Awaiting product image

Article: RELEVANCE: A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat

€3.03

SKU: product-article-21045 Category:

Description

RELEVANCE: A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat

Related products